Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allergy TherapeuticsLSE:AGY -0.37% Receivables Turnover is 5.25 as of Dec. 2025. The stock has 7 warning signs investors should review. Among 950 Drug Manufacturers companies, Allergy Therapeutics ranks better than 75.58% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Allergy Therapeutics's Revenue for the
six
months ended in Dec. 2025 was £36.28 Mil. Allergy Therapeutics's average Accounts Receivable for the
six
months ended in Dec. 2025 was £6.91 Mil.
Hence, Allergy Therapeutics's Receivables Turnover for the
six
months ended in Dec. 2025 was 5.25.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Allergy Therapeutics Receivables Turnover Related Terms
Allergy Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:AGY vs ZTS, UTHR, VTRS: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (LSE:AGY) has a Receivables Turnover of 5.25 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #232 out of 950 companies in the Drug Manufacturers industry, placing it in the top 24.4%.
Is Allergy Therapeutics' Receivables Turnover too high?
Allergy Therapeutics' current Receivables Turnover is 5.25. The Drug Manufacturers industry median Receivables Turnover is 5.07. Allergy Therapeutics' value of 5.25 is 3.6% above this industry median. Based on the distribution chart, Allergy Therapeutics ranks #232 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Allergy Therapeutics' Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #232 out of 950 companies for Receivables Turnover. This places Allergy Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.07. Allergy Therapeutics' value of 5.25 is 3.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Allergy Therapeutics's current Receivables Turnover of 5.25 is 3.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current Receivables Turnover is 5.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.05 — trading 79.3% above its estimated fair value. The current Receivables Turnover is 5.25 and 3.6% above the Drug Manufacturers industry median of 5.07. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current Receivables Turnover is 5.25 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 
